Login to Your Account



UNEXPECTED BIDDING WAR WITH ENDO

Amid uncertainties, Teva surprises with Nupathe counter bid

By Jennifer Boggs
Managing Editor

Thursday, January 9, 2014
With investors still awaiting the appointment of a new CEO following Jeremy Levin’s abrupt departure in October, Teva Pharmaceutical Industries Ltd. made an unsolicited $114 million cash offer for Nupathe Inc., starting a surprise bidding war with Endo Health Solutions, which inked a deal last month to acquire the small specialty pharma firm for $105 million in up-front cash.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription